New methods to improve drug delivery and immune response in pancreatic cancer
Official title: Novel Strategies to Enhance Drug Delivery and Tumor Immunogenicity in Pancreatic Cancer
Funded at Univ of Arkansas for Med Scis · NIH-10908003 · Data updated 2026-11-12
This study is testing a new virus treatment for pancreatic cancer that aims to attack cancer cells directly and boost the body's immune response, with the hope of making treatments more effective and helping patients live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,377,000 |
| NIH project number | 1DP2CA301099-01 |
| Project ID | NIH-10908003 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who have limited treatment options.
✕Less likely to help
Patients with early-stage pancreatic cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on developing a novel oncolytic virus platform to treat pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. The approach involves using a modified virus that can effectively target and kill cancer cells while also enhancing the immune response against the tumor. By breaking down the dense tumor stroma, which often hinders treatment effectiveness, this strategy aims to improve the delivery of therapeutic agents and increase immune cell infiltration into the tumor. Patients may benefit from improved treatment outcomes and potentially longer survival rates.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise with oncolytic viruses in treating other types of cancer, suggesting potential success for this novel approach in pancreatic cancer.
Where this research is happening
-
Univ of Arkansas for Med Scis
Little Rock, United States Active
Researchers
- Principal investigator: Nagalo, Bolni Marius — Univ of Arkansas for Med Scis
- Study coordinator: Nagalo, Bolni Marius
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.